Summit Therapeutics, Inc. (SMMT)
13.73
-0.60
(-4.19%)
USD |
NASDAQ |
Aug 28, 16:00
13.73
0.00 (0.00%)
After-Hours: 20:00
Summit Therapeutics Cash from Operations (Quarterly) : -140.55M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -140.55M |
| March 31, 2026 | -122.29M |
| December 31, 2025 | -99.03M |
| September 30, 2025 | -95.14M |
| June 30, 2025 | -70.52M |
| March 31, 2025 | -61.17M |
| December 31, 2024 | -47.38M |
| September 30, 2024 | -32.24M |
| June 30, 2024 | -32.85M |
| March 31, 2024 | -30.13M |
| December 31, 2023 | -18.19M |
| September 30, 2023 | -15.37M |
| June 30, 2023 | -29.92M |
| March 31, 2023 | -13.13M |
| December 31, 2022 | 4.030M |
| September 30, 2022 | -6.643M |
| June 30, 2022 | -17.98M |
| March 31, 2022 | -19.00M |
| December 31, 2021 | -7.849M |
| September 30, 2021 | -23.16M |
| June 30, 2021 | -19.46M |
| March 31, 2021 | -20.67M |
| December 31, 2020 | -8.843M |
| Date | Value |
|---|---|
| September 30, 2020 | -17.54M |
| June 30, 2020 | -14.60M |
| March 31, 2020 | -8.562M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | -5.630M |
| October 31, 2018 | -4.996M |
| July 31, 2018 | -13.99M |
| April 30, 2018 | -9.743M |
| January 31, 2018 | -8.085M |
| October 31, 2017 | -13.69M |
| July 31, 2017 | 11.93M |
| April 30, 2017 | -9.926M |
| January 31, 2017 | -7.972M |
| October 31, 2016 | 36.25M |
| July 31, 2016 | -4.115M |
| April 30, 2016 | -9.091M |
| January 31, 2016 | -8.285M |
| October 31, 2015 | -6.406M |
| July 31, 2015 | -4.964M |
| April 30, 2015 | -5.815M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0336M |
| Brainstorm Cell Therapeutics, Inc. | -0.895M |
| Kezar Life Sciences, Inc. | -7.445M |
| Protara Therapeutics, Inc. | -15.39M |
| Clene, Inc. | -2.578M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 222.41M |
| Cash from Financing (Quarterly) | 230.57M |
| Free Cash Flow | -458.40M |
| Free Cash Flow Per Share (Quarterly) | -0.1818 |
| Free Cash Flow to Equity (Quarterly) | -141.81M |
| Free Cash Flow to Firm (Quarterly) | -141.46M |
| Free Cash Flow Yield | -4.36% |